/images/ppid_59c68470-image-176577507285878066.webp)
What is the story about?
Shares of Biocon Ltd. gained in early trade on Monday, December 16, after the company said it has launched its Glucagon-like Peptide-1 (GLP-1) for diabetes and obesity in Netherlands via its distribution partner Pharmamedic BV.
The drug-device combination will be marketed in the Netherlands under the brand names Diavorin for diabetes and Vobexoryn for chronic weight management, Biocon said in an exchange filing.
The launch comes after the approval from Medicines Evaluation Board (MEB), Netherlands, earlier this year, and will mark the first country in the EU where the company will directly launch Liraglutide under its own brand, it added.
"With our vertically-integrated, end-to-end capabilities, we are uniquely positioned to deliver high-quality, affordable metabolic treatments at scale," Siddharth Mittal, the CEO and managing director of Biocon, said.
Biocon on Saturday, December 13, said its subsidiary Biocon Biologics has inked a settlement and licence agreement to commercialise the biosimilar Aflibercept globally.
The new agreement with Regeneron and Bayer for the biosimilar in Europe and the rest of the world follows a previous settlement covering the US and Canada. With this, Biocon Biologics will commercialise Yesafili, a biosimilar Aflibercept (40mg/ml), in all countries across the globe.
Yesafili is a vascular endothelial growth factor inhibitor used to treat multiple ophthalmology conditions, the company said.
Shares of Biocon gave up early gains to trade 0.3% lower on Monday at ₹385.3. The stock is down 8.5% in the last one month.
Also Read:Federal Bank share price target raised by UBS to ₹310 anticipating better operating metrics
The drug-device combination will be marketed in the Netherlands under the brand names Diavorin for diabetes and Vobexoryn for chronic weight management, Biocon said in an exchange filing.
The launch comes after the approval from Medicines Evaluation Board (MEB), Netherlands, earlier this year, and will mark the first country in the EU where the company will directly launch Liraglutide under its own brand, it added.
"With our vertically-integrated, end-to-end capabilities, we are uniquely positioned to deliver high-quality, affordable metabolic treatments at scale," Siddharth Mittal, the CEO and managing director of Biocon, said.
Biocon on Saturday, December 13, said its subsidiary Biocon Biologics has inked a settlement and licence agreement to commercialise the biosimilar Aflibercept globally.
The new agreement with Regeneron and Bayer for the biosimilar in Europe and the rest of the world follows a previous settlement covering the US and Canada. With this, Biocon Biologics will commercialise Yesafili, a biosimilar Aflibercept (40mg/ml), in all countries across the globe.
Yesafili is a vascular endothelial growth factor inhibitor used to treat multiple ophthalmology conditions, the company said.
Shares of Biocon gave up early gains to trade 0.3% lower on Monday at ₹385.3. The stock is down 8.5% in the last one month.
Also Read:Federal Bank share price target raised by UBS to ₹310 anticipating better operating metrics
/images/ppid_59c68470-image-176577270305673594.webp)
/images/ppid_59c68470-image-176576759335592594.webp)
/images/ppid_59c68470-image-176577007364637765.webp)
/images/ppid_a911dc6a-image-176576404906795740.webp)
/images/ppid_a911dc6a-image-176568607393189770.webp)
/images/ppid_a911dc6a-image-176567826447456484.webp)
/images/ppid_59c68470-image-176556502963067735.webp)
